Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Patient goals and preferences matter considerably
Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results
And we think we see these effects for alcohol use, for other drugs over a more sustained period of time
Consult a doctor
GLP-2 receptor expression in excitatory and inhibitory enteric neurons and its role in mouse duodenum contractility
US$ 27.64
US$ 20.62
US$ 28.33
US$ 25.69
US$ 24.28
US$ 28.54
